Immatics IMTX
NASDAQ IMTX
$9.56 +0.10 (+1.06%)
As of: Sep 4, 2026 · 3:59 PM EDT

Immatics (IMTX) Income towards Parent Company (2019 - 2026)

Immatics (IMTX) posted Income towards Parent Company of -$41.2 million for Q4 2025, up 30.55% sequentially from -$59.4 million in Q3 2025, and down 186.03% YoY from $47.9 million in Q4 2024.

Analysis

Immatics (IMTX) Income towards Parent Company (2019 - 2026) Analysis & Trends

Immatics has reported Income towards Parent Company for 7 years, with the latest figure at -$41.2 million in Q4 2025.

  • Quarterly Income towards Parent Company fell 186.03% year-over-year to -$41.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$224.3 million (down 1516.27% YoY) and the FY2025 annual result came in at -$221.9 million, down 1447.51% from the prior year.
  • Income towards Parent Company improved to -$41.2 million in Q4 2025 per IMTX's latest filing, from -$59.4 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $96.1 million in Q1 2022 and troughed at -$79.6 million in Q2 2025.
  • A 5-year average of -$16.9 million and a median of -$23.4 million in 2022 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2022 and 2024: Income towards Parent Company soared 449.38% in 2022, then slumped 1188763.81% in 2024.
  • Over 5 years, Income towards Parent Company stood at -$19.2 million in 2021, then surged by 111.78% to $2.3 million in 2022, then tumbled by 1343.81% to -$28.1 million in 2023, then soared by 270.4% to $47.9 million in 2024, then sank by 186.03% to -$41.2 million in 2025.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$41.2 million, -$59.4 million, and -$79.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Immatics 1.17 Bn 711.21 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -72.64 Mn
Mar 31, 2026 -67.69 Mn
Dec 31, 2025 -41.24 Mn
Sep 30, 2025 -59.39 Mn
Jun 30, 2025 -79.63 Mn
Mar 31, 2025 -41.92 Mn
Dec 31, 2024 47.94 Mn
Sep 30, 2024 -9.41 Mn
Jun 30, 2024 -19.38 Mn
Mar 31, 2024 -3.32 Mn
Dec 31, 2023 -47.73 Mn
Sep 30, 2023 -28.84 Mn
Jun 30, 2023 -26.80 Mn
Mar 31, 2023 -279.07
Dec 31, 2022 2.26 Mn
Sep 30, 2022 -19.98 Mn
Jun 30, 2022 -12.47 Mn
Mar 31, 2022 96.14 Mn
Dec 31, 2021 194.34 Mn
Sep 30, 2021 -32.08 Mn